Identification and characterization of the transient receptor potential (TRP) channels in the intervertebral disc
OPEN ACCESS
Loading...
Author / Producer
Date
2020
Publication Type
Doctoral Thesis
ETH Bibliography
yes
Citations
Altmetric
OPEN ACCESS
Data
Rights / License
Abstract
Low back pain (LBP) has a high prevalence and is a major public health problem globally.
Intervertebral disc degeneration (IVD), which is the central cause of LBP, is a natural
process with an early onset. Due to the rapidly aging population in the western society, it
is predicted that occurrences of LBP as well as its related costs will further increase, causing
a high economic burden on the individual and the society. Biomechanical, biological and
genetic factors have an impact on the development of painful IVD degeneration (also called
degenerative disc disease). However, treatment options are limited. Therefore, there is a
clear need for advancing our understanding of IVD degeneration and designing novel
treatment strategies. Transient receptor potential (TRP) channels constitute a family of
Ca2+ permeable cell membrane receptors and have recently emerged as potential
contributors to tissue homeostasis, inflammation and pain. TRP channels were investigated
as biomarkers and potential therapeutic targets in many other tissues, but so far, their role
remains largely unknown in the IVD. This thesis attempts to address this knowledge gap.
The objective of this thesis was to identify and characterize TRP channels and proinflammatory
factors in the IVD, with the goal to evaluate their therapeutic potential.
In the first study, the occurrences of inflammatory processes and the expression of TRPC6
and TRPV4 in human degenerated tissue from the lumbar and cervical IVDs were measured
and compared. Aside from genes with known implication in degenerative disc disease (DDD)
or disc herniation (DH), four previously not recorded genes from the interferon and TRP
families (IFNα1, IFNα8, IFNβ1, TRPC6) could be detected in the human degenerated IVD
tissue. A correlation between gene expression and age (IL-15) and IVD degeneration grade
(IFNα1, IL-6, IL-15, TRPC6), but not Modic grade, was identified. Significant differences
were found between cervical and lumbar IVDs (IL-15), nucleus and annulus (IL-6, TNF-α,
TRPC6), single-level and multi-level surgery (IL-6, IL-8) as well as DDD and DH (IL-8),
while sex had no effect. Multiple gene-gene pair correlations, either between different
cytokines (e.g. IL-6 and IL-8) or between cytokines and TRP channels (e.g. TRPC6 and
IL-15/IL-8/IL-6), exist in the disc. Presented findings support the importance of IL-6 and
IL-8 during IVD degeneration, but additionally demonstrate a potential pro-inflammatory
role of IL-15 and interferon type I as well as a mechanistic role of TRPC6 in the disease.
This study concluded that despite existing tissue- or patient-specific differences, novel anti-inflammatory or TRP-modulatory strategies for the treatment of disc pathologies may be
applicable independently of the spinal region.
In the second study, the gene and protein expression pattern of currently known TRP
channels in non-degenerated and degenerated human IVD tissue was analyzed. Patient- and
tissue- specific characteristics, such as age, IVD degeneration grade, pain intensity and
chronicity and others were included in the analysis. For the first time we could show that
26 out of 28 currently known TRP channels are expressed in the IVD on the gene level,
thereby revealing novel therapeutic candidates from the TRPC, TRPM and TRPML
subfamilies. TRPC6, TRPM2 and TRPML1 displayed enhanced gene and protein
expression in degenerated IVDs as compared with non-degenerated IVDs. Furthermore, the
gene expression of TRPC6 and TRPML1 was influenced by the IVD degeneration grade.
Pain intensity and/or chronicity affected the gene and/or protein expression of TRPC6,
TRPM2 and TRML1, therefore suggesting their therapeutic potential. Interestingly,
decreased gene expression of TRPM2 was observed in patients treated with steroids. This
is the first study to present the link between TRP channels and pain in the IVD. Thus,
these results represent the current benchmark for the TRP channel expression pattern in
the IVD. Our findings support the importance of TRP channels in IVD homeostasis and
pathology, and their possible application as pharmacological targets for the treatment of
IVD degeneration and LBP.
The objective of the third study was to investigate the effect of hypo-osmotic stress, which
is one of the main hallmarks of IVD degeneration, on the gene expression pattern and
calcium signaling of TRPV4 and TRPM7 channels in bovine IVD cells. As the first in the
field, we presented a complete screening of currently known TRP channel in bovine IVD
cells. In line with the results obtained in human IVD tissue, TRPC1, TRPM7 and TRPV4
were overall the most highly expressed TRP channels in bovine IVD cells. We determined
that TRPV4 gene expression was downregulated in hypo-osmotic condition, whereas its
Ca2+ flux increased. RNA sequencing identified over 3000 up- or down-regulated targets,
from which we selected aggrecan, ADAMTS9 and IL-6 and investigated whether their
altered gene expression is mediated through either the TRPV4 or TRPM7 channel, using
specific activators and inhibitors (GSK1016790A/ GSK2193874 for TRPV4 and Naltriben/
NS8593 for TRPM7). Application of TRPV4 selective activator (GSK1016790A) induced
the expression of IL-6 under iso-osmotic condition, proportionally to hypo-osmotic stimulation alone, indicating that this effect might be TRPV4-mediated. However, the
application of TRPV4 selective blocker (GSK2193874) failed to inhibit the increase of IL-6
under hypo-osmotic condition. A treatment with TRPM7-activator did not cause significant
changes in the gene expression of tested targets. We concluded that although TRPV4 and
TRPM7 are likely involved in osmosensing in the IVD, neither of them mediates hypo-osmotically-
induced gene expression changes of aggrecan, ADAMTS9 and IL-6.
This thesis has made several significant contributions to the field of spine research. Through
a detailed identification and characterization of TRP channels in the IVD, it revealed their
important role in IVD degeneration. It demonstrated that the expression levels of TRP
channels and pro-inflammatory factors may depend on the specific characteristics of the
IVD tissue (e.g. lumbar versus cervical, degeneration grade) or patients (e.g. pain
intensity/chronicity). Importantly, results of these experiments highlighted novel
therapeutic targets from the TRPC, TRPM and TRPML family, which are not only linked
to low back pain intensity or chronicity, but also to the level of inflammation. These findings
may contribute to the design of new biomarker-based tests and help develop novel
pharmacological treatments for painful IVD degeneration and LBP. Moreover, RNA
sequencing data presented in this thesis can serve spine scientist as a source for further
research.
In conclusion, IVD tissue- and/or patient-dependent expression pattern of TRP channels
presented over the course of this study suggests that TRP channels have a potential to
become novel therapeutic targets in painful IVD degeneration. Their pharmacological
modulation may prove beneficial in treating pain and inflammation, could contribute to the
regulation of the IVD tissue homeostasis and might ultimately change clinical practice
related to discogenic back pain in the future.
Permanent link
Publication status
published
External links
Editor
Contributors
Book title
Journal / series
Volume
Pages / Article No.
Publisher
ETH Zurich
Event
Edition / version
Methods
Software
Geographic location
Date collected
Date created
Subject
Intervertebral disc (IVD); Intervertebral Disc (IVD) Degeneration; intervertebral disc herniation; inflammation; Inflammaging; mechanical loading; mechanobiology; degenerative disc disease (DDD); Low Back Pain; Cervical spine; Lumbar spine; transient receptor potential (TRP) channels; TRPV4; TRPC6; TRPM7; hypo-osmolarity; osmosensing; IL-6; IL-15; cytokines; pro-inflammatory cytokines; Membrane receptor; therapeutic target; Human intervertebral disc cells; bovine intervertebral disc cells; GSK2193874; GSK1016790A; Naltriben
Organisational unit
09597 - Würtz, Karin (SNF-Professur) (ehemalig) / Würtz, Karin (SNF-Professur) (former)
Notes
Funding
163678 - Unlocking the mechanisms of mechanotransduction in degenerative disc disease (TRIPDISC) (SNF)